Local Company Will Showcase its Tech at NIH Event
Inanovate, Inc, a South Dakotan biotechnology company developing diagnostic tests for cancer, has been awarded a booth at BIO 2016 by the National Institutes of Health. The booth will help showcase Inanovate’s new blood test for detecting breast cancer recurrence in its earliest stages, when it may be more effectively treated.
Inanovate is also using this opportunity to showcase partnerships with local institutions.
Inanovate works closely with Sanford Health and the South Dakota Governor’s Office of Economic Development, and will be using its exposure at BIO 2016 to highlight the strengths and value of these organizations to the national and international Life Science community.
“Clinical trials for our breast cancer diagnostic and monitoring test are progressing very positively,” says David Ure, President and CEO of Inanovate. “Exposure at a conference like BIO, especially with the backing of the NIH, is a nice boost for our company as well as our commercial and investment partners.“
Inanovate will be
finalizing a private placement this summer, open primarily to SD based
investors. The offering will provide additional resource in support of the next
phase of clinical trials for Inanovate’s breast cancer test, as the company
prepares for commercial launch.